The Thesis
ResMed is a medical device company that creates the machines and masks people use to treat sleep apnea and other breathing disorders. The company generated $4.69 billion in revenue last year, representing 11% growth as it consolidated its lead in the global sleep market. Reaching a record $1.29 billion in free cash flow last year marks the structural shift where ResMed moved from a hardware supplier to a highly profitable health technology platform.
The bet here comes down to four specific things.
In our view, ResMed is a multi-year compounder driven by its shift into high-margin digital health software and recurring mask sales. The case for owning this only gets stronger if the company can prove that weight loss drugs are actually bringing more patients into the diagnostic funnel. We think the market is currently underestimating how much profit ResMed can generate from its existing user base through better software and replacement cycles.
Numbers at a Glance
What does it do?
ResMed is a mature business that earns money by selling continuous positive airway pressure (CPAP) machines and the recurring masks and accessories needed to use them. When a patient is diagnosed with sleep apnea, they are prescribed a device that blows air through a mask to keep their airway open during sleep. ResMed sells the initial hardware to medical equipment providers who then distribute it to patients. The real profit engine is the recurring sale of masks and filters, which patients must replace every few months to maintain hygiene and effectiveness. ResMed also runs a software business that monitors patient data in the cloud, helping doctors ensure their patients actually use the therapy.
Where does revenue come from?
The vast majority of revenue comes from the Sleep and Respiratory Care segment, which includes both hardware devices and recurring mask sales. The company also operates a Software as a Service (SaaS) segment that provides management software to out-of-hospital care providers. ResMed generates revenue globally, with roughly 55% of sales coming from the United States and Canada, while the remaining 45% is earned in international markets.
Revenue Breakdown
Revenue by Geography
Who are its customers?
ResMed serves millions of individual patients and a global network of durable medical equipment (DME) providers who manage their care. The company has more than 170 million people in its cloud-connected ecosystem who generate health data every night. On the software side, ResMed's SaaS segment serves home health agencies, hospices, and skilled nursing facilities through brands like Brightree and MatrixCare. These businesses pay ResMed subscription fees to manage their administrative workflows and patient records.
What gives it staying power?
ResMed has a wide moat built on high switching costs for patients and healthcare providers. Once a patient is on the ResMed cloud platform, their data is integrated with their doctor’s office and their insurance provider. Switching to a different brand of machine would mean breaking that data link and potentially disrupting their insurance coverage or clinical monitoring.
Where is it headed?
ResMed is focusing on digital health and expanding into the treatment of chronic obstructive pulmonary disease (COPD) and insomnia. Management is betting that cloud-connected data will prove their devices save the healthcare system money, justifying higher prices and better reimbursement. They are also investing heavily in AI to help identify undiagnosed patients who are currently using weight loss drugs but still suffer from breathing issues.
Revenue is growing at a double-digit pace as ResMed captures market share from competitors in the sleep apnea space. The 11% revenue increase last year to $4.69 billion shows the company is successfully navigating the return to normal supply chains. This growth is increasingly driven by higher-margin mask sales rather than just one-time machine purchases.
Free cash flow more than doubled last year to $1.29 billion, proving the business is a highly efficient cash generator. This massive jump in cash quality occurred as the company resolved previous supply chain backlogs and improved its inventory management. ResMed now converts more than 25% of its revenue directly into free cash flow.
The balance sheet is exceptionally strong with a debt-to-equity ratio of only 0.13x. This low leverage gives ResMed the flexibility to continue its aggressive share buyback program while still funding research and development. The company currently carries very little net debt relative to its $1.40 billion in annual net income.
ResMed is a financially dominant business that has reached a new level of profitability through its cloud-connected ecosystem.
Gross margins reached 61.7% over the last twelve months, reflecting a shift toward higher-priced devices and recurring software revenue. This expansion shows that ResMed has significant pricing power and is successfully offsetting inflation through manufacturing efficiency. The company is extracting more profit from every dollar of sales than it did three years ago.
The long-term impact of GLP-1 weight loss drugs on the total number of sleep apnea patients remains the single biggest risk. If a significant portion of patients cured of obesity no longer require CPAP therapy, ResMed's long-term growth runway could be cut short. While management argues these drugs act as a diagnostic funnel, the real impact on device replacement cycles won't be clear for several years.
The global sleep apnea and respiratory care market is roughly $10B today, growing ~8% annually, and is on track to reach $15B by 2030. This is a highly attractive industry because pricing power is structural, driven by medical necessity and limited insurance-approved manufacturers. Regulatory hurdles and the need for complex global distribution networks prevent new entrants from easily competing. ResMed stands as the clear global leader, holding roughly half the market and benefiting from a massive runway as only 20% of the estimated 1 billion people with sleep apnea have been diagnosed.
This market is rationally structured but requires immense technical and regulatory expertise to maintain a competitive position. Barriers to entry are high because products require FDA approval and must integrate with complex insurance reimbursement systems.
Philips(PHG) remains the most dangerous threat, but its massive product recall has significantly damaged its brand and allowed ResMed to gain share. Fisher & Paykel(FPH) competes effectively in the mask market by focusing on superior comfort and specialized patient needs. Inspire Medical(INSP) offers a surgical alternative that bypasses the mask entirely, threatening ResMed's most profitable recurring revenue stream.
ResMed is gaining share and holding ground as its primary competitor remains sidelined by regulatory issues. The company's 11% revenue growth outpaces the broader industry average.
The primary source of protection is high switching costs created by ResMed's cloud-connected software ecosystem. Once a patient’s data is flowing through AirView to their doctor and insurance payer, changing devices creates significant administrative friction. ResMed has over 170 million cloud-connected users supporting this edge.
A 19.6% ROIC and 61.7% gross margins prove that ResMed's advantage is structural and not just a temporary result of competitor stumbles. These numbers show the company earns a high return on the money it reinvests, which is a hallmark of a durable moat. The consistent free cash flow growth confirms this is a high-quality compounding business.
The moat is strengthening as ResMed’s software integration makes its ecosystem increasingly difficult for competitors to displace.
Delivered 11% revenue growth while expanding gross margins to 61.7% in FY2024.
Returned $1.29 billion in free cash flow through buybacks and dividends.
CEO Michael Farrell holds a significant stake and has led the digital pivot.
Capital Allocation Track Record
Michael Farrell has successfully transformed ResMed from a hardware manufacturer into a digital health leader with a clear focus on recurring revenue. Management has demonstrated exceptional discipline by focusing on high-margin mask sales and software rather than chasing low-margin hardware volume. The decision to capitalize on competitor recalls while maintaining a strong balance sheet has positioned the company as the undisputed leader in its field.
© 2026 ClearThesis.ai · Report generated on May 27, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.